5-ethoxyquinoline | 92287-48-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-ethoxyquinoline
• CAS: 92287-48-4
• 化学式: C₁₁H₁₁NO
• mdl: MFCD28337286
• 分子量: 173.214
• InChiKey: KTOOFZYSSPILRY-UHFFFAOYSA-N

物化性质

• 沸点：
  294.4±13.0 °C(Predicted)
• 密度：
  1.101±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-ethoxyquinoline 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 三乙胺 、 间氯过氧苯甲酸 、 三氯氧磷 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 30.5h， 生成 5-ethoxy-2-(pyridine-3-ylethynyl)quinoline
  参考文献：
  名称：

  Synthesis and biological evaluation of 2-(arylethynyl)quinoline derivatives as mGluR5 antagonists for the treatment of neuropathic pain

  摘要：

  We described here the synthesis and biological evaluation of mGluR5 antagonists containing a quinoline ring structure. Using intracellular calcium mobilization assay (FDSS assay), we identified compound 5n, showing high inhibitory activity against mGluR5. In addition, it was found that compound 5n has excellent stability profile. Finally, this compound exhibited favorable analgesic effects in spinal nerve ligation model of neuropathic pain, which is comparable to gabapentin. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.12.056
• 作为产物：
  描述：

  5-羟基喹啉 、 碘乙烷 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 8.0h， 以87%的产率得到5-ethoxyquinoline
  参考文献：
  名称：

  [EN] COMBINATION PRODUCT FOR THE TREATMENT OF CANCER DISEASES
  [FR] PRODUIT DE COMBINAISON POUR LE TRAITEMENT DE MALADIES CANCÉREUSES

  摘要：

  本发明涉及一种用于治疗癌症疾病的联合疗法产品。具体而言，该发明涉及一种抗PD-L1抗体和一种Formula(I)的MCT4抑制剂的组合。该治疗组合可用于治疗对PD-L1和/或MCT4表达呈阳性的癌症患者。

  公开号：

  WO2021249969A1

文献信息

• 2-(Substituted ethynyl)quinoline Derivatives as mGLUr5 Antagonists
  申请人：Korea Institute of Science and Technology

  公开号：US20140206876A1

  公开（公告）日：2014-07-24

  Provided is a 2-(substituted ethynyl)quinoline derivative having an mGluR5 antagonistic activity and pharmaceutically acceptable salts thereof. The compound of the present invention can be useful as a medicament for treating and preventing mGluR5 receptor-mediated diseases such as Alzheimer's disease, senile dementia, Parkinson's disease, L-DOPA-induced dyskinesia, Huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, anxiety disorder, depression, neuropathic pain, drug dependence, fragile X syndrome, autism, migraine and gastroesophageal reflux disease (GERD).

  提供的是一种具有mGluR5拮抗活性和其药用盐的2-(取代乙炔基)喹啉衍生物。本发明的化合物可用作治疗和预防mGluR5受体介导的疾病，如阿尔茨海默病、老年性痴呆、帕金森病、L-多巴诱导的运动障碍、亨廷顿舞蹈症、肌萎缩侧索硬化、多发性硬化、精神分裂症、焦虑症、抑郁症、神经病性疼痛、药物依赖、脆性X综合征、自闭症、偏头痛和胃食管反流病（GERD）的药物。
• [EN] DISUBSTITUTED ALKYNE DERIVATIVES<br/>[FR] DÉRIVÉS D'ALCYNE DISUBSTITUÉS
  申请人：MERCK PATENT GMBH

  公开号：WO2020127960A1

  公开（公告）日：2020-06-25

  The present invention relates to disubstituted alkyne derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.

  本发明涉及二取代炔衍生物。这些化合物对预防和/或治疗多种医学状况包括高增殖性疾病和疾病具有用处。
• Synthesis of a novel water-soluble cylindrical macrotricyclic host and its complexation with N-methylquinolinium and N-methylisoquinolinium salts: formation of 1 : 2 complexes in water
  作者：Fei Zeng、Chuan-Feng Chen

  DOI：10.1039/c4ob02533d

  日期：——

  A novel water-soluble cylindrical macrotricyclic host containing one central cavity and two dibenzo-24-crown-8 lateral cavities was synthesized. It could form 1 : 2 complexes with N-methylquinolinium salts or N-methylisoquinolinium salts in water solution and in the solid state, in which multiple hydrogen-bonding and π–π stacking interactions between the host and the guests played an important role

  合成了一种新型的水溶性圆柱形大三环主体，该主体包含一个中心腔和两个二苯并-24-冠-8侧腔。它可以与N-甲基喹啉鎓盐或N-甲基异喹啉鎓盐在水溶液中和固态形成1：2的配合物，其中主体与客体之间的多个氢键和π–π堆积相互作用起着重要作用。此外，可以通过改变溶液的pH来实现主体与客体之间的复合物的复合和解复合，并且还可以用肉眼观察该过程。
• MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
  申请人：Melinta Therapeutics, Inc.

  公开号：US20150158901A1

  公开（公告）日：2015-06-11

  The present invention provides macrocyclic compounds useful as therapeutic agents of the formula: or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof, wherein T, R 1 , R 2 , R 3 , D, E, F, and G are as defined herein. More particularly, these compounds are useful as anti-infective, antiproliferative, anti-inflammatory and prokinetic agents.

  本发明提供了用作治疗剂的大环化合物，其化学式为：其中T，R1，R2，R3，D，E，F和G的定义如本文所述，或其药学上可接受的盐，酯，N-氧化物或前药。更具体地说，这些化合物可用作抗感染，抗增殖，抗炎和促动力剂。
• 1-Carbacephalosporin antibiotics
  申请人：ELI LILLY AND COMPANY

  公开号：EP0232623A1

  公开（公告）日：1987-08-19

  7β-Acylamino-3-alkoxycarbonyl-(and 3-keto)-1-carba (1-dethia)-3-cephem-4-carboxylic acids and derivatives and related 3-substituted compounds are provided as antibiotics useful for treating infections in man and other animals. Pharmaceutical formulations comprising the antibiotics, intermediates, and a process for their preparation are also provided.

  本发明提供了 7β-乙酰氨基-3-烷氧基羰基-（和 3-酮基）-1-咔巴（1-二硫杂）-3-头孢-4-羧酸及其衍生物和相关的 3-取代化合物，作为抗生素可用于治疗人类和其他动物的感染。此外，还提供了包含这些抗生素、中间体及其制备工艺的药物制剂。